

Boukje A G Dijkstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7883454/publications.pdf>

Version: 2024-02-01

36
papers

748
citations

567281

15
h-index

552781

26
g-index

39
all docs

39
docs citations

39
times ranked

669
citing authors

#	ARTICLE	IF	CITATIONS
1	Regression-Based Normative Data for the Montreal Cognitive Assessment (MoCA) and Its Memory Index Score (MoCA-MIS) for Individuals Aged 18–91. <i>Journal of Clinical Medicine</i> , 2022, 11, 4059.	2.4	12
2	The Course of Cognitive Performance during Inpatient Treatment in Patients with Alcohol Use Disorder with No, Mild or Major Neurocognitive Disorders. <i>Alcohol and Alcoholism</i> , 2021, 56, 89-100.	1.6	12
3	Success Rates of Monitoring for Healthcare Professionals with a Substance Use Disorder: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 264.	2.4	7
4	Characterization of the GHB Withdrawal Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 2333.	2.4	9
5	Palliative care for patients with substance use disorder and multiple problems: a qualitative study on experiences of healthcare professionals, volunteers and experts-by-experience. <i>BMC Palliative Care</i> , 2020, 19, 8.	1.8	19
6	Psychometric properties of the Montreal Cognitive Assessment (MoCA) in healthy participants aged 18–70. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 293-300.	2.4	46
7	The Montreal Cognitive Assessment (MoCA) as a cognitive screen in addiction health care: A validation study for clinical practice. <i>Journal of Substance Use</i> , 2019, 24, 47-54.	0.7	16
8	Palliative care for people with substance use disorder and multiple problems: a qualitative study on experiences of patients and proxies. <i>BMC Palliative Care</i> , 2019, 18, 56.	1.8	14
9	A Qualitative Approach in Understanding Illness Perception and Treatment Needs in Patients with Gamma Hydroxybutyrate Use Disorder. <i>European Addiction Research</i> , 2019, 25, 248-255.	2.4	6
10	Prevalence of cognitive impairment in patients with substance use disorder. <i>Drug and Alcohol Review</i> , 2019, 38, 435-442.	2.1	85
11	Detoxification of a Patient With Comorbid Dependence on Phenibut and Benzodiazepines by Tapering With Baclofen. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 511-514.	1.4	10
12	Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial. <i>CNS Drugs</i> , 2018, 32, 437-442.	5.9	22
13	Palliative care for patients with a substance use disorder and multiple problems: a study protocol. <i>BMC Palliative Care</i> , 2018, 17, 97.	1.8	8
14	Treatment delivery of the community reinforcement approach in outpatient addiction treatment. <i>Evaluation and Program Planning</i> , 2018, 70, 61-66.	1.6	5
15	Treatment consumption and treatment re-enrollment in GHB-dependent patients in The Netherlands. <i>Drug and Alcohol Dependence</i> , 2017, 176, 96-101.	3.2	31
16	Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project. <i>Drug and Alcohol Dependence</i> , 2017, 170, 164-173.	3.2	45
17	Pharmacological Treatment in γ -Hydroxybutyrate (GHB) and γ -Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention. <i>CNS Drugs</i> , 2017, 31, 51-64.	5.9	44
18	Treatment of substance use disorders: Effects on patients with higher or lower levels of PTSD symptoms. <i>Addictive Behaviors</i> , 2017, 74, 122-126.	3.0	6

#	ARTICLE	IF	CITATIONS
19	Psychiatric comorbidity, psychological distress, and quality of life in gamma-hydroxybutyrate-dependent patients. <i>Journal of Addictive Diseases</i> , 2017, 36, 72-79.	1.3	8
20	Epidemiology of Gamma-Hydroxybutyrate (GHB) Use and Misuse and Characteristics of GHB-Dependent Inpatients. , 2016, , 491-499.		0
21	Gamma-Hydroxybutyrate Abuse and Dependence. , 2016, , 379-387.		2
22	The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review. <i>Neuropsychobiology</i> , 2016, 73, 65-80.	1.9	47
23	The Effect of Co-occurring Substance Use on Gamma-hydroxybutyric Acid Withdrawal Syndrome. <i>Journal of Addiction Medicine</i> , 2016, 10, 229-235.	2.6	14
24	Good Psychometric Properties of the Addiction Version of the Revised Illness Perception Questionnaire for Health Care Professionals. <i>PLoS ONE</i> , 2016, 11, e0164262.	2.5	10
25	Baclofen as Relapse Prevention in the Treatment of Gamma-Hydroxybutyrate Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 313-318.	1.4	12
26	Baclofen as relapse prevention in the treatment of Gamma- Hydroxybutyrate (GHB) dependence: an open label study. <i>BMC Psychiatry</i> , 2015, 15, 91.	2.6	15
27	A Case Series of Pharmaceutical Gamma-Hydroxybutyrate in 3 Patients With Severe Benzodiazepine-Resistant Gamma-Hydroxybutyrate Withdrawal in the Hospital. <i>Psychosomatics</i> , 2015, 56, 404-409.	2.5	19
28	Decision rules for GHB (gamma-hydroxybutyric acid) detoxification: A vignette study. <i>Drug and Alcohol Dependence</i> , 2014, 135, 146-151.	3.2	12
29	Patients' Improvements Measured With the Pleasant Activities List and the Community Reinforcement Approach Happiness Scale. <i>Addictive Disorders and Their Treatment</i> , 2012, 11, 6-13.	0.5	4
30	Gamma-Hydroxybutyrate Detoxification by Titration and Tapering. <i>European Addiction Research</i> , 2012, 18, 40-45.	2.4	49
31	Opioid Detoxification: From Controlled Clinical Trial to Clinical Practice. <i>American Journal on Addictions</i> , 2010, 19, 283-290.	1.4	6
32	Prediction of Abstinence in Opioid-Dependent Patients. <i>Journal of Addiction Medicine</i> , 2008, 2, 194-201.	2.6	18
33	Prediction of withdrawal symptoms during opioid detoxification. <i>Journal of Opioid Management</i> , 2008, 4, 311-319.	0.5	16
34	Psychometric Evaluation of the Dutch Version of the Subjective Opiate Withdrawal Scale (SOWS). <i>European Addiction Research</i> , 2007, 13, 81-88.	2.4	18
35	Does naltrexone affect craving in abstinent opioid-dependent patients?. <i>Addiction Biology</i> , 2007, 12, 176-182.	2.6	22
36	A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. <i>Addiction</i> , 2005, 100, 1868-1874.	3.3	76